Brooks Laboratories (BOM:533543) Debt-to-Equity : 0.09 (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Brooks Laboratories Debt-to-Equity?

Brooks Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹52.9 Mil. Brooks Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹3.6 Mil. Brooks Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹655.9 Mil. Brooks Laboratories's debt to equity for the quarter that ended in Mar. 2024 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Brooks Laboratories's Debt-to-Equity or its related term are showing as below:

BOM:533543' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.18 Max: 0.4
Current: 0.09

During the past 13 years, the highest Debt-to-Equity Ratio of Brooks Laboratories was 0.40. The lowest was 0.01. And the median was 0.18.

BOM:533543's Debt-to-Equity is ranked better than
73.85% of 845 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs BOM:533543: 0.09

Brooks Laboratories Debt-to-Equity Historical Data

The historical data trend for Brooks Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brooks Laboratories Debt-to-Equity Chart

Brooks Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.28

0.40

0.29

0.09

Brooks Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															N/A	0.09	0.05	N/A	0.09

Competitive Comparison of Brooks Laboratories's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brooks Laboratories's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Brooks Laboratories's Debt-to-Equity falls into.

Brooks Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Brooks Laboratories's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(52.854	+	3.565)	/	655.853
	=	0.09

Brooks Laboratories's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(52.854	+	3.565)	/	655.853
	=	0.09

Brooks Laboratories (BOM:533543) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Brooks Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Brooks Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Brooks Laboratories (BOM:533543) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Brooks Laboratories Ltd (BOM:533543) » Definitions » Debt-to-Equity

Traded in Other Exchanges

BROOKS:India

Address

Off. Andheri Kurla Road, 201, The Summit Business Park, Behind Guru Nanak Petrol Pump, Andheri (East), Mumbai, MH, IND, 400 093

Website

https://www.brookslabs.net

Brooks Laboratories Ltd is an Indian company operating in the healthcare sector. The company is engaged in the formulation, development, production, and export of drugs and pharmaceuticals. It has manufacturing sites located in Baddi, Himachal Pradesh, and Vadodara, Gujarat. It manufactures drugs in a variety of forms, including tablets, dry syrup, injections, liquid injections, dry powder injections, eye drops, and ear drops. Its products include carbapenem and penicillins.

Brooks Laboratories (BOM:533543) Headlines

No Headlines